Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 32

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 32
---
 to meet its obligations under the Merger Agreement to use commercially reasonable efforts to achieve the milestones. AstraZeneca also filed a claim for breach of the representations in the Merger Agreement.- A trial was held in July 2023.- In September 2024, the court issued a partial decision, concluding that the first milestone in the amount of $130m was achieved, and that AstraZeneca had breached its contractual obligation to use commercially reasonable efforts to achieve the milestones. The court requested additional briefing regarding damages and further proceedings regarding AstraZeneca's claim for breach.- In June 2025, the court issued a further decision awarding an additional $181m in damages on its September 2024 breach determination. Additional proceedings regarding AstraZeneca's claim for breach are ongoing.​​​​​​​
42

#### Government investigations and proceedings​​​​​Legal proceedings brought against AstraZeneca​Texas Qui Tam, USConsidered to be a contingent liability- In December 2022, AstraZeneca was served with an unsealed civil lawsuit brought by qui tam relators on behalf of the State of Texas in Texas state court, which alleges that AstraZeneca engaged in unlawful marketing practices.- In July 2025, the State of Texas sought to intervene in the matter.- Trial is scheduled for December 2025.​​​​Legal proceedings brought by AstraZeneca​340B State Litigation, USConsidered to be a contingent asset- AstraZeneca has filed lawsuits against Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, Missouri, Nebraska, Utah, and West Virginia challenging the constitutionality of each state's 340B statute.- In the Arkansas matter, trial is scheduled for September 2025 and the state has moved to dismiss AstraZeneca's complaint. In the separate Arkansas administrative proceeding, the commissioner issued a cease-and-desist order in April 2025 requiring AstraZeneca to pause its 340B policy in Arkansas. AstraZeneca has appealed this decision.- In Kansas, after obtaining a stipulation from the state that AstraZeneca's policy does not violate the Kansas 340B statute, AstraZeneca agreed to dismiss its complaint.- In Louisiana, the court granted the state's motion for summary judgment. AstraZeneca has filed an appeal.- In Maryland, the state has moved to dismiss AstraZeneca's complaint and the court has denied AstraZeneca's preliminary injunction motion.- In Minnesota, the court found that the defendant